Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

Phase 4

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 3(2)

Phase 4(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT02299050Phase 4Completed

Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

Role: collaborator

NCT02078440Phase 1Completed

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

Role: lead

NCT00377676Phase 3Completed

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes

Role: lead

NCT00441363Phase 3Terminated

Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin

Role: lead

All 4 trials loaded